… Fox has received consultant fees from Allozyne, Avanir, Biogen Idec, EMD Serono,
Novartis, Questcor, Teva, and XenoPort; has received research support from Biogen Idec and …

Background: Susac syndrome (SS) is a self-limited syndrome, presumably autoimmune,
consisting of a clinical triad of encephalopathy, branch retinal artery occlusions, and hearing …

Multiple sclerosis is a major cause of neurological disability, which accrues predominantly
during progressive forms of the disease. Although development of multifocal inflammatory …

Background There is increasing evidence that B lymphocytes are involved in the pathogenesis
of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal …

Background BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing–remitting
multiple sclerosis, which is commonly treated with parenteral agents (interferon or …

Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …

This article reports the results of a meta-analysis of experimental studies which have
examined ten different factors felt to influence response rates to mail surveys. The form of meta-…

Objective Degeneration of chronically demyelinated axons is a major cause of irreversible
neurological disability in multiple sclerosis (MS) patients. Development of neuroprotective …

The anterior cruciate ligament has a complex fiber anatomy and is not considered to be a
uniform structure. Current anterior cruciate ligament reconstructions succeed in stabilizing the …

We describe a directed evolution approach that should find broad application in generating
enzymes that meet predefined process-design criteria. It augments recombination-based …